Telehealth use will suffer global divergence for years

2019 ◽  
Keyword(s):  
Developing Countries ◽  
World Health Organisation ◽  
Personal Health Information ◽  
World Health ◽  
Personal Health ◽  
Virtual Technology ◽  
Content Type ◽  
Industry Collaboration ◽  
The World ◽  
Regulatory Bodies

Subject Telehealth outlook. Significance The World Health Organisation (WHO) defines telehealth as involving the use of telecommunications and virtual technology to deliver healthcare outside of traditional facilities. Telehealth is becoming a critical tool for addressing health inequalities but how it is accessed varies widely between developed and developing countries. Impacts Rural parts of developing countries will lag the most on telehealth due to infrastructure gaps. Greater cross-industry collaboration is needed on privacy safeguards for personal health information. Developing-country health systems will face pressure to develop accreditation and regulatory bodies specifically for telehealth.

Global lessons from Ebola crisis may be ignored

2015 ◽  
Keyword(s):  
Health Services ◽  
World Health Organisation ◽  
World Health ◽  
Health Priorities ◽  
Local Health ◽  
International Organisations ◽  
Content Type ◽  
The World ◽  
National Governments

Subject Lessons from the Ebola crisis. Significance The Ebola epidemic in West Africa caught national governments and international organisations off-guard. As the epidemic begins to abate in the affected countries, the World Health Organisation (WHO) has begun an internal process to learn lessons for future global health emergencies. However, many of the required responses were well-known before the Ebola outbreak but ignored. Shifting entrenched political attitudes will be a challenge. Impacts Popular distrust of local health services continues to mar comprehensive detection of Ebola infections in affected countries. Re-building local health services will be distorted if the Ebola crisis dominates planning over long-term health priorities. However, donors tend to prefer orientation towards disease-specific programmes and interventions over strengthening health systems.

North America's cannabis sector has enormous scope

2017 ◽  
Keyword(s):  
World Health Organisation ◽  
World Health ◽  
Content Type ◽  
North American Market ◽  
The Us ◽  
The World ◽  
Working Age ◽  
Recreational Marijuana ◽  
Drugs And Crime ◽  
Recreational Use

Subject The US cannabis market. Significance The World Health Organisation reports that cannabis is the most widely used psychoactive controlled substance across the world. Indeed, the UN Office on Drugs and Crime estimates that in 2014, 182.5 million working-age people used recreational marijuana. North America is the world's largest market for marijuana, cannabis's smoked herbal form, and legalisation for both medicinal and recreational use is building momentum, rapidly creating a massive new industry. Impacts The share of the global population using cannabis is around 3.8%, translating into a North American market of at least 18 million users. Canada is legalising cannabis next year while 29 US states and the District of Columbia have legalised medical or recreational use. Full US legalisation remains uncertain as the federal prohibition remains in place.

Similarities and differences in managing the Covid-19 crisis and climate change risk

2020 ◽  
Vol 24 (10) ◽  
pp. 2597-2614
Author(s):  
Maria Laura Ruiu ◽  
Massimo Ragnedda ◽  
Gabriele Ruiu
Keyword(s):  
Climate Change ◽  
Risk Communication ◽  
Action Plan ◽  
World Health Organisation ◽  
World Health ◽  
Communication Model ◽  
Content Type ◽  
The Public ◽  
The World ◽  
Similarities And Differences

Purpose This paper investigates both similarities and differences between two global threats represented by climate change (CC) and Covid-19 (CV). This will help understand the reasons behind the recognition of the CV as a pandemic that requires global efforts, whereas efforts to tackle climate change still lack such urgency. This paper aims to answer to the following questions: What are the elements that make CV restrictions acceptable by both the public and policymakers? and What are the elements that make CC restrictions not acceptable? Design/methodology/approach This paper analyses the situation reports released by the World Health Organisation between the 11th of March (declaration of pandemic) and the 22nd of April, and their associated documents such as the Strategic Preparedness and Response Plan (WHO), the Risk Communication and Community Engagement Action Plan (WHO) and its updated version (WHO) and the Handbook for public health capacity-building (WHO). The analysis ends one week after President Trump’s announcement to suspend US funding to WHO (Fedor and Manson, 2020) and his support to public demonstrations against restrictions. Findings The application of the second stage of the “Crisis and Emergency Risk Communication” model identifies five lessons that can be learned from this comparison. These relate to the necessity to simultaneously warn (about the severity of a threat) and reassure (by suggesting specific courses of action) the public; the need for multilevel collaboration that integrates collective and individual actions; the capacity to present cohesive messages to the public; the risk of politicisation and commodification of the issue that might undermine global efforts to tackle the threat; and the capacity to trigger individual responses through the promotion of self-efficacy. Originality/value This paper identifies both similarities and differences between CC and CV managements to understand why the two threats are perceived and tackled in different ways. The analysis of official documents released by both the World Health Organisation and the Intergovernmental Panel on Climate CV outbreak as a crisis, whereas climate change is still anchored to the status of a future-oriented risk.

Overcoming barriers to disseminate effective smoking cessation treatments globally

2020 ◽  
Vol 20 (3) ◽  
pp. 235-247
Author(s):  
Sudhanshu Patwardhan ◽  
Jed E. Rose
Keyword(s):  
Health Care ◽  
Smoking Cessation ◽  
World Health Organisation ◽  
World Health ◽  
National Guidelines ◽  
Nicotine Replacement ◽  
Content Type ◽  
National Implementation ◽  
The World ◽  
Health Programmes

Purpose The purpose of this paper is to review the barriers in the dissemination of effective smoking cessation treatments and services globally. Offering tobacco users help to stop using tobacco is a key demand reduction measure outlined under Article 14 of the World Health Organisation (WHO) Framework Convention on Tobacco Control (FCTC). Implementing Article 14 can reap great dividends for the billion plus tobacco users around the world and their families, friends and societies. Design/methodology/approach A review of the status of the global implementation of Article 14 using available literature on smoking cessation products, services and national guidelines. Discussing innovative approaches being currently explored in South Asia that can lead to faster adoption and implementation of Article 14 globally. Findings Major gaps remain in cessation products’ availability and resource allocation for cessation services globally. Current licensed products are falling short on delivering and sustaining smoking cessation. Innovation in cessation products and services needs to build on learnings in nicotine pharmacokinetics, behavioural insights from consumer research and tap into 21st century tools such as mobile based apps. National implementation of FCTC’s Article 14 needs to follow guidelines that encourage integration into existing health programmes and health-care practitioners’ (HCPs) upskilling. Originality/value Smoking cessation is a desirable health outcome and nicotine replacement products are a means of achieving cessation through tobacco harm reduction. E-cigarettes are sophisticated nicotine replacement products. Innovation is urgently needed to fill the gaps in smoking cessation products and services, and for converting global policy into local practice. In low- and middle-income countries (LMICs), HCPs’ knowledge, attitudes and practice regarding tobacco use and cessation may hold the key to rapidly scaling up cessation support and delivery to achieve FCTC objectives sooner. Additionally, HCPs can play an important role in offering smoking cessation support in existing national health programmes for TB, cancer screening and maternal and child health. Also, widely prevalent smartphone devices may deliver smoking cessation through telemedicine in LMICs sooner, leapfrogging the hurdles of the existing health-care infrastructure.

scholarly journals Access to Medicines and Medical Equipment during COVID-19: Searching Compatibility between the WTO and the WHO

2022 ◽  
pp. 097492842110684
Author(s):  
Mrityunjay Kumar ◽  
Ayesha Fatma ◽  
Nalin Bharti
Keyword(s):  
Developing Countries ◽  
Medical Equipment ◽  
Qualitative Content Analysis ◽  
Low Cost ◽  
World Health Organisation ◽  
Developed Countries ◽  
Access To Medicines ◽  
World Health ◽  
The World

Affordable access to medicines is a key determinant of a country’s resilience to health crises. The modern hyper-connected international trade and production networks have a vital role to play in ensuring this accessibility, especially in the context of a pandemic. This article focuses on the medicines and medical equipment and analyses the synergistic role of the two international organisations—The World Trade Organisation (WTO) and The World Health Organisation (WHO), in assuring affordable access to these goods globally. WHO is responsible for global healthcare regulations; however, the medical supply chain originates in a few developed countries, manufactured in bulk (in case of medicine) at low cost in developing countries, and finally traded worldwide. Here, the role of WTO comes—it facilitates global trade cooperation and intellectual property rights monitoring, both key elements in medical goods production and trading. Despite the need for cooperation in mitigating COVID-19, much of the global response to COVID-19 has been fragmented and inward-looking. This lack of coordination has serious repercussions especially for developing countries. We use qualitative content analysis methodology, connecting concepts of cooperation theory and global governance, to identify the joint role of the two organisations in fostering global cooperation in medical goods accessibility.

A Collaborative Study to Establish the Second International Standard for Streptokinase

1990 ◽  
Vol 64 (02) ◽  
pp. 267-269 ◽  
Author(s):  
A B Heath ◽  
P J Gaffney
Keyword(s):  
High Purity ◽  
Collaborative Study ◽  
World Health Organisation ◽  
World Health ◽  
Clot Lysis ◽  
Current Standard ◽  
International Standard ◽  
Accelerated Degradation ◽  
The World ◽  
International Collaborative Study

SummaryAn International Standard for Streptokinase - Streptodomase (62/7) has been used to calibrate high purity clinical batches of SK since 1965. An international collaborative study, involving six laboratories, was undertaken to replace this standard with a high purity standard for SK. Two candidate preparations (88/826 and 88/824) were compared by a clot lysis assay with the current standard (62/7). Potencies of 671 i.u. and 461 i.u. were established for preparations A (88/826) and B (88/824), respectively.Either preparation appeared suitable to serve as a standard for SK. However, each ampoule of preparation A (88/826) contains a more appropriate amount of SK activity for potency testing, and is therefore preferred. Accelerated degradation tests indicate that preparation A (88/826) is very stable.The high purity streptokinase preparation, coded 88/826, has been established by the World Health Organisation as the 2nd International Standard for Streptokinase, with an assigned potency of 700 i.u. per ampoule.

Comparative docking of SARS-CoV-2 receptors antagonists from repurposing drugs

2020 ◽  
Author(s):  
Micael Davi Lima de Oliveira ◽  
Kelson Mota Teixeira de Oliveira
Keyword(s):  
World Health Organisation ◽  
World Health ◽  
Lung Cells ◽  
The Novel ◽  
High Modulation ◽  
Main Protease ◽  
The World ◽  
Novel Coronavirus ◽  
Viral Receptors ◽  
Theoretical Results

According to the World Health Organisation, until 16 June, 2020, the number of confirmed and notified cases of COVID-19 has already exceeded 7.9 million with approximately 434 thousand deaths worldwide. This research aimed to find repurposing antagonists, that may inhibit the activity of the main protease (Mpro) of the SARS-CoV-2 virus, as well as partially modulate the ACE2 receptors largely found in lung cells, and reduce viral replication by inhibiting Nsp12 RNA polymerase. Docking molecular simulations were performed among a total of 60 structures, most of all, published in the literature against the novel coronavirus. The theoretical results indicated that, in comparative terms, paritaprevir, ivermectin, ledipasvir, and simeprevir, are among the most theoretical promising drugs in remission of symptoms from the disease. Furthermore, also corroborate indinavir to the high modulation in viral receptors. The second group of promising drugs includes remdesivir and azithromycin. The repurposing drugs HCQ and chloroquine were not effective in comparative terms to other drugs, as monotherapies, against SARS-CoV-2 infection.

Use of Phosphatidylcholine in the Treatment of Localized Fat Deposits. Results and expectations

2017 ◽  
Vol 68 (7) ◽  
pp. 1438-1441 ◽  
Author(s):  
Sorin Berbece ◽  
Dan Iliescu ◽  
Valeriu Ardeleanu ◽  
Alexandru Nicolau ◽  
Radu Cristian Jecan
Keyword(s):  
World Health Organisation ◽  
Normal Weight ◽  
World Health ◽  
Basic Substance ◽  
Physical Exercises ◽  
Fat Deposits ◽  
The World ◽  
The Common ◽  
Global Health Problem ◽  
Over Time

Obesity represents a global health problem. According to the latest studies released by the World Health Organisation (WHO), 1.7 billion currently in excess of normal weight individuals, of which approx. 75% are overweight (body mass index - BMI 25 to 30). The common form of excess adipose tissue manifestation in overweight individuals is localized fat deposits with high (abdominal) or low (buttocks and thighs) disposition. Although the overweight can be corrected relatively easy by changing behavioral habits or food, a constant physical exercises program or following a diet food are not accessible to all through the efforts of will, financial and time involved. Several methods have been studied and tested over time to eliminate more or less invasive fat deposits with varying efficacy and adverse effects. Chemical lipolysis using phosphatidylcholine as the basic substance was initially used in hypercholesterolemia and its complications and was rapidly adopted in mesotherapy techniques for the treatment of fat deposits. This study reveals the results obtained using Dermastabilon on a sample of 16 patients, the time allocated to treatment and discomfort being minimal, and rapid and notable results. There were no side effects.

Heterocycles in the Treatment of Neglected Tropical Diseases

2020 ◽  
Vol 27 ◽  
Author(s):  
Kush K. Maheshwari ◽  
Debasish Bandyopadhyay
Keyword(s):  
Developing Countries ◽  
Heterocyclic Compounds ◽  
Neglected Tropical Diseases ◽  
World Health ◽  
Current Status ◽  
Poor People ◽  
Tropical Diseases ◽  
Concise Review ◽  
The World ◽  
Health Organization

Background: Neglected tropical diseases (NTDs) affect a huge population of the world and majority of the victims belong to the poor community of the developing countries. Until now, the World Health Organization (WHO) has identified 20 tropical diseases as NTDs that must be addressed with high priority. However, many heterocyclic scaffolds have demonstrated potent therapeutic activity against several NTDs. Objective: There are three major objectives: (1) To discuss the causes, symptoms, and current status of all the 20 NTDs; (2) To explore the available heterocyclic drugs, and their mechanism of actions (if known) that are being used to treat NTDs; (3) To develop general awareness on NTDs among the medicinal/health research community and beyond. Methods: The 20 NTDs have been discussed according to their alphabetic orders along with the possible heterocyclic remedies. Current status of treatment with an emphasis on the heterocyclic drugs (commercially available and investigational) has been outlined. In addition, brief discussion of the impacts of NTDs on socio-economic condition is included. Results: NTDs are often difficult to diagnose and the problem is worsened by the unhealthy hygiene, improper awareness, and inadequate healthcare in the developing countries where these diseases primarily affect poor people. The statistics include duration of suffering, numbers affected, and access to healthcare and medication. The mechanism of actions of various heterocyclic drugs, if reported, have been briefly summarized. Conclusion: Scientists and pharmaceutical corporations should allocate more resources to reveal the in-depth mechanism of actions of many heterocyclic drugs that are currently being used for the treatment of NTDs. Analysis of current heterocyclic compounds and development of new medications can help in the fight to reduce/remove the devastating effects of NTDs. An opinion-based concise review has been presented. Based on available literature, this is the first effect to present all the 20 NTDs and related heterocyclic compounds under the same umbrella.

Sign in / Sign up

Export Citation Format

Share Document